Entromix Completes Pre-Clinical Trials Successfully:-
The Russian vaccine against cancer entromix has successfully passed pre-clinical trials. It is now ready for use as per the FMBA of Russia. Entroix is an intramuscular injection and has already entered early clinical use at several oncology centers in Russia. Patients with lung, breast, colurectal or pancreatic cancers can easily benefit from it. High-risisk patients with hereditary cancer syndromes and those with chemotherapy resistance cancers can now take the vaccine. However, it awaits approval from the DGCA and the health ministry in India.
Who Can Benefit from Entromix?:-
At this point, my colleague Shireen who tracks the health ministry for us is going to be giving us those details. Shireen, if if this is going to be clear, of course, it’s going to be landmark, but what are you picking up from the health ministry sources? How soon can we expect this entire process to be concluded in our country? So well uh right now what we are learning is that Russia has officially announced that as far as cancer is concerned this is going to be a major groundbreaking vaccine because after years of research and pre clinical trials the vaccine has shown at least 100% efficacy but this is too early because this is phase one is what we are being told. uh it is being rolled out in in a clinical manner in Russia.
India Yet to Approve Entromix:-
Russia has to of course approach the Russia Federation of Medicine has to approach India uh with the vaccine and then they have to get an approval from the BCGA and then further from health ministry. So the entire process could take about a few months or by the end of this year we could uh uh see that a green signal could be given to this medicine. But this is of course a landmark uh you know uh as far as vaccines in India in across the world is concerned regarding cancer. This is one of the first of its kind and this could in fact be a major boost as far as fighting cancer across the world is concerned. So uh we are of course awaiting once it will be rolled out in Russia itself then in other countries and when Russia approaches India health ministry and DGC approval is going to be awaited and we have to see whether that will be given or not and Sharin there has been a lot of stress from the government and from the health ministry on you know fighting cancer for example when we talk about uh the cancer drugs and especially as far as cervical cancer is concerned.
100% Efficacy in Early Trials—but Caution Remains:-
So you do expect that the government would want to speed up this process. Absolutely. Because when we talk about cancer in general, there are of course uh in India, of course, the rate has increased of people who have been affected by multiple cancers across the country. And this is a concerning situation for India especially for the underprivileged who have to of course uh shell out a lot of money uh as far as treating cancer is concerned. So it is one of the major priorities for health ministry to make the medicines affordable to make the treatment of cancer avail more more affordable and that is why a number of vaccines and medicines have already been given a green signal in India which are of international brands or are of other countries.
Government Likely to Expedite Review Process:-
There is in fact our collaboration that is uh going on with us as well as far as the cancer medicines are concerned and now this particular uh vaccines which is endromix it’s going to be of course a groundbreaking one because this treats cancer according to the tailored you know the way the patient needs it if the patient is suffering of cervical cancer or for that matter matter lung cancer it is going to be tailored according to his or her treatment ment. So that is what is going to be a landmark you know decision as far as this vaccine is concerned but of course it’s awaited approval in India and like you said Palvi that our fight is against cancer in India and that’s why we are going to of course see that this is in all likelihood being given a major approval in the country.